Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): From bench to bedside

摘要: Thyroid cancer is the most common endocrine malignancy, representing 1% of all human malignancies; its incidence has been escalating worldwide during last decades. In recent years important molecular pathways contributing to tumor progression and worse survival rates have identified in iodine-refractory differentiated thyroid carcinoma (DTC) with consequent development therapeutics target these specific oncogenic pathways. For example, a positive correlation found between expression vascular endothelial growth factor (VEGF) more aggressive phenotype DTC. This led widespread adoption VEGF-targeted preclinical clinical settings. this review we will provide an overview different aspects use VEGF-pathway-oriented treatments DTC particular focus on future prospects.